Pulmonx Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and thank you for joining us at Canaccord Genuity's 2026 MedTech, Diagnostics, Digital Health, and Services Forum. My name is John Young. I am one of the MedTech analysts here. I am very pleased to be joined today by Derrick Sung, Chief Operating Officer and Chief Financial Officer of Pulmonx. Derrick was Pulmonx's CFO from 2019 to 2023, including the company's 2020 IPO, and then rejoined in November 2025. For those less familiar with the story, Pulmonx is a commercial-stage medical device company focused on severe emphysema. Its product, the Zephyr Valve, is a one-way valve placed in the lung through a bronchoscope that blocks off the diseased part of the lung so healthier parts work better and patients can breathe more easily. Derrick, thanks for being here today. Pulmonx just reported its first year-over-year revenue growth after declines in Q4, Q1, and Q2.
Looking back on the one year you and Glen have returned, what was the core problem that you found, and how much of the turnaround is behind you versus ahead?
Sure, and thanks for having me, John, and thanks for that introduction and the brief overview on the company. When Glen and I returned a year ago, what we found was that the company had just lost focus. We were trying to do too many things, trying to do it all at once, and while much of it was well-intentioned, the end result was that we saw a rapid slowdown in our sales. We saw our expenses kind of go in the opposite direction, and those increased, and we saw turnover across our employee base, specifically in our U.S. sales force, which is where we saw the biggest slowdown happen. We came in with a turnaround plan, and it was a really simple three-step turnaround plan. Step one was to realign our cost structure.
We had just, again, started spending way out in front of revenues that just never materialized, and so we took out roughly 10% of our recurring costs, brought our cash burn down. We burned $32 million last year. We are going to burn closer to $22 million this year, so nearly a 30% reduction in our cash burn. That was step one. The second step was we wanted to strengthen our balance sheet. We had $40 million of debt that was coming due earlier this year. We refinanced that debt. We kicked it out five years, interest only, so we do not have to worry about it until 2031. In that process, we also got access to an additional $20 million of undrawn capital that will give us a little buffer.
With those two steps from a financial perspective, we went from having less than a year's worth of cash to now we have the capital that we need to get to cash flow break-even. Those two pieces of our turnaround are largely complete. The third and most important step to our turnaround is, of course, getting our company back to positive sales growth. This is a work in progress, but we are making really good progress. We have refilled the majority of the open positions in our U.S. sales team. We have refocused our U.S. sales strategy, and as you mentioned, we are seeing early signs of good progress. We returned to growth for the first time, which is a real milestone, since we got back here in Q3.
Even prior to that, every quarter since we have been here, we have seen a nice year-over-year improvement in our revenue profile. Plenty of work to be done, but we are on track with the plan that we laid out for ourselves, and we are feeling good about it.
Definitely want to dive deeper into those, but maybe also taking a step back. You rejoined as both CFO, but now also COO. Maybe you could just talk about your increased responsibilities, and also, what brought you back to Pulmonx? What did you see that made you want to rejoin the company too?
Sure. What brought me back was, look, I knew the market opportunity was large. I knew our technology worked. Our technology, our Zephyr Valve technology, it is serving a huge unmet need in these patients with severe emphysema. These are patients who really have exhausted all medical options available to them. Most of them are not candidates for a surgical procedure. What our Zephyr Valve does is it really rolls back the clock on their disease. It gives them their lives back. So it is a critical unmet need. The product works, and we know it works, and it has been proven in multiple clinical studies. When I looked at the company and was making my decision to come back, what I knew was that the market had not really changed, that the broader end market had not changed. We were not facing any new large competitive threat that was not there before.
There wasn't any disruptive reimbursement that wasn't there before. None of these things had changed. I felt confident that it was something that we could fix. It was something internal that we could come back and fix it. I also felt, from a personal perspective, that there was just a lot of value that we could create here. Pulmonx is, we're a $90 million plus revenue company. We're a 75% plus gross margin company. If we can get back to positive growth and sustainable growth, which I do believe we can, I felt like there was a lot of value to be created. That was the reasons why, what drove me back here. In terms of roles and responsibilities, when Glen and I kind of laid out our plan, we took a divide and conquer approach.
Glen is spending a lot of his time focused on the commercial turnaround, so he's getting involved in the day-to-day operations of our commercial team. He's driving that turnaround in the U.S. sales force, managing directly our area vice presidents on the U.S. side. To give him that leverage and to give him the bandwidth, I've taken on responsibilities for all of the non-commercial operations within the company, so R&D, clinical, quality, regulatory, and manufacturing ops, in addition to the finance and G&A functions. Of course, we all have really great leaders and great talent in place running all of those functions, and those leaders are really executing and bringing our execution to kind of the next level. That's how we've divided things up, and it seems to be working out pretty well.
Got it. In Q3, your revenue roughly beat consensus by about $1 million, yet full-year revenue guidance of $90 million-$92 million was reiterated. How has your approach to forecasting changed since you got back? Maybe just talk about your guidance philosophy so far.
Yeah. We have always been, since we were here last and currently, very focused on delivering on our commitments, focused on not getting out in front of our skis in terms of what we're committing to. Especially now, I think we know that we're a show-me story at this point, and we want our results to speak for themselves rather than our words. That continues to be our philosophy. We came in with a plan, as I described, at the start of this year. We set out a guidance range at the start of this year. The guidance that you mentioned, $90 million-$92 million, we haven't deviated from the start of this year. That's a reflection of the fact that we're on track with the plan that we laid out for ourselves.
Got it. A big part of that plan is the U.S. commercial sales force. As you highlighted, there was a lot of turnover when you came in, 50% in 2025, to be specific. The mean and median tenure now, I think, is at 1.8 and 1.2 years. What did you and Glen do to stabilize the sales force? What are you doing differently in hiring, training, and retention, and what are you seeing today that makes you optimistic?
Sure. There were a lot of reasons for the sales force turnover that we saw last year. It was kind of a confluence of events, almost a perfect storm, that included changes in roles and changes to comp plans and to what the sales reps were being asked to do and how they were being managed. I think the first thing we did was we really took kind of a back-to-basics approach and tried to address these issues that were causing a lot of the angst. We shuffled the organization a bit. As I mentioned, Glen got involved. We have new sales managers in place. We've been really largely successful in refilling all of the open territories that were opened up. At this point, we've got nearly all of our territories filled in the U.S.
There's always going to be some level of turnover, which I think is healthy in any medical device sales organization, but we're back to kind of normalized turnover rates, if you will. We're focused on getting these folks up to speed, so we have worked on optimizing our training program to get these folks up to speed. We do have a lot of new folks, as you mentioned, right? Average tenure has gone down. We not only have new territory managers, new sales reps, we also have new sales managers in place as well. It's all a matter of getting these folks up to speed, up the learning curve. That can take some time. But I think we're making good progress, and it feels like morale has improved, and we're really in the right direction.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
